السوق العالمية لأدوية الإنفلونزا – اتجاهات الصناعة والتوقعات حتى عام 2031

TABLE 1 GLOBAL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 2 GLOBAL INFLUENZA A IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 3 GLOBAL INFLUENZA B IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 4 GLOBAL INFLUENZA C IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 5 GLOBAL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 6 GLOBAL INFLUENZA A IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 7 GLOBAL DRUGS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 8 GLOBAL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 9 GLOBAL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 10 GLOBAL TRIVALENTIN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 11 GLOBAL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 12 GLOBAL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 13 GLOBAL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 14 GLOBAL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 15 GLOBAL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 16 GLOBAL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 17 GLOBAL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 18 GLOBAL ORAL MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 19 GLOBAL INTRAMUSCULAR IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 20 GLOBAL INTRADERMAL IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 21 GLOBAL INTRANASAL IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 22 GLOBAL INTRAVENOUS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 23 GLOBAL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 24 GLOBAL PEDIATRICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 25 GLOBAL ADULTS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 26 GLOBAL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 27 GLOBAL HOSPITALS IN GLOBAL INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 28 GLOBAL HOMECARE IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 29 GLOBAL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 30 GLOBAL DIRECT TENDER IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 31 GLOBAL RETAIL SALES IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 32 GLOBAL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 33 GLOBAL INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 34 NORTH AMERICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 35 NORTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 36 NORTH AMERICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 37 NORTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 38 NORTH AMERICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 39 NORTH AMERICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 40 NORTH AMERICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 41 NORTH AMERICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 42 NORTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 43 NORTH AMERICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 44 NORTH AMERICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 45 NORTH AMERICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 46 NORTH AMERICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 47 NORTH AMERICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 48 NORTH AMERICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 49 NORTH AMERICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 50 NORTH AMERICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 51 U.S. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 52 U.S. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 53 U.S. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 54 U.S. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 55 U.S. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 56 U.S. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 57 U.S. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 58 U.S. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 59 U.S. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 60 U.S. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 61 U.S. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 62 U.S. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 63 U.S. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 64 U.S. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 65 U.S. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 66 U.S. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 67 MEXICO INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 68 MEXICO INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 69 MEXICO VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 70 MEXICO QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 71 MEXICO TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 72 MEXICO BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 73 MEXICO MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 74 MEXICO VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 75 MEXICO INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 76 MEXICO LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 77 MEXICO DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 78 MEXICO INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 79 MEXICO INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 80 MEXICO INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 81 MEXICO INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 82 MEXICO RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 83 CANADA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 84 CANADA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 85 CANADA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 86 CANADA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 87 CANADA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 88 CANADA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 89 CANADA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 90 CANADA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 91 CANADA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 92 CANADA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 93 CANADA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 94 CANADA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 95 CANADA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 96 CANADA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 97 CANADA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 98 CANADA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 99 EUROPE INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 100 EUROPE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 101 EUROPE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 102 EUROPE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 103 EUROPE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 104 EUROPE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 105 EUROPE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 106 EUROPE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 107 EUROPE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 108 EUROPE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 109 EUROPE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 110 EUROPE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 111 EUROPE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 112 EUROPE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 113 EUROPE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 114 EUROPE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 115 EUROPE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 116 U.K. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 117 U.K. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 118 U.K. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 119 U.K. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 120 U.K. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 121 U.K. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 122 U.K. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 123 U.K. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 124 U.K. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 125 U.K. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 126 U.K. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 127 U.K. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 128 U.K. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 129 U.K. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 130 U.K. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 131 U.K. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 132 GERMANY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 133 GERMANY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 134 GERMANY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 135 GERMANY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 136 GERMANY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 137 GERMANY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 138 GERMANY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 139 GERMANY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 140 GERMANY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 141 GERMANY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 142 GERMANY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 143 GERMANY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 144 GERMANY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 145 GERMANY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 146 GERMANY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 147 GERMANY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 148 SPAIN INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 149 SPAIN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 150 SPAIN VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 151 SPAIN QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 152 SPAIN TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 153 SPAIN BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 154 SPAIN MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 155 SPAIN VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 156 SPAIN INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 157 SPAIN LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 158 SPAIN DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 159 SPAIN INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 160 SPAIN INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 161 SPAIN INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 162 SPAIN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 163 SPAIN RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 164 ITALY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 165 ITALY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 166 ITALY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 167 ITALY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 168 ITALY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 169 ITALY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 170 ITALY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 171 ITALY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 172 ITALY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 173 ITALY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 174 ITALY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 175 ITALY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 176 ITALY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 177 ITALY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 178 ITALY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 179 ITALY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 180 FRANCE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 181 FRANCE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 182 FRANCE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 183 FRANCE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 184 FRANCE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 185 FRANCE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 186 FRANCE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 187 FRANCE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 188 FRANCE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 189 FRANCE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 190 FRANCE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 191 FRANCE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 192 FRANCE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 193 FRANCE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 194 FRANCE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 195 FRANCE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 196 RUSSIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 197 RUSSIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 198 RUSSIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 199 RUSSIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 200 RUSSIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 201 RUSSIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 202 RUSSIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 203 RUSSIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 204 RUSSIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 205 RUSSIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 206 RUSSIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 207 RUSSIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 208 RUSSIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 209 RUSSIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 210 RUSSIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 211 RUSSIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 212 NETHERLANDS INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 213 NETHERLANDS INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 214 NETHERLANDS VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 215 NETHERLANDS QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 216 NETHERLANDS TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 217 NETHERLANDS BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 218 NETHERLANDS MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 219 NETHERLANDS VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 220 NETHERLANDS INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 221 NETHERLANDS LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 222 NETHERLANDS DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 223 NETHERLANDS INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 224 NETHERLANDS INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 225 NETHERLANDS INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 226 NETHERLANDS INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 227 NETHERLANDS RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 228 TURKEY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 229 TURKEY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 230 TURKEY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 231 TURKEY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 232 TURKEY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 233 TURKEY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 234 TURKEY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 235 TURKEY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 236 TURKEY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 237 TURKEY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 238 TURKEY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 239 TURKEY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 240 TURKEY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 241 TURKEY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 242 TURKEY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 243 TURKEY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 244 SWITZERLAND INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 245 SWITZERLAND INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 246 SWITZERLAND VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 247 SWITZERLAND QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 248 SWITZERLAND TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 249 SWITZERLAND BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 250 SWITZERLAND MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 251 SWITZERLAND VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 252 SWITZERLAND INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 253 SWITZERLAND LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 254 SWITZERLAND DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 255 SWITZERLAND INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 256 SWITZERLAND INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 257 SWITZERLAND INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 258 SWITZERLAND INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 259 SWITZERLAND RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 260 BELGIUM INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 261 BELGIUM INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 262 BELGIUM VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 263 BELGIUM QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 264 BELGIUM TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 265 BELGIUM BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 266 BELGIUM MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 267 BELGIUM VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 268 BELGIUM INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 269 BELGIUM LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 270 BELGIUM DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 271 BELGIUM INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 272 BELGIUM INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 273 BELGIUM INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 274 BELGIUM INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 275 BELGIUM RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 276 REST OF EUROPE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 277 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 278 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 279 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 280 ASIA-PACIFIC VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 281 ASIA-PACIFIC QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 282 ASIA-PACIFIC TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 283 ASIA-PACIFIC BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 284 ASIA-PACIFIC MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 285 ASIA-PACIFIC VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 286 ASIA-PACIFIC INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 287 ASIA-PACIFIC LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 288 ASIA-PACIFIC DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 289 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 290 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 291 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 292 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 293 ASIA-PACIFIC RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 294 JAPAN INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 295 JAPAN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 296 JAPAN VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 297 JAPAN QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 298 JAPAN TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 299 JAPAN BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 300 JAPAN MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 301 JAPAN VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 302 JAPAN INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 303 JAPAN LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 304 JAPAN DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 305 JAPAN INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 306 JAPAN INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 307 JAPAN INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 308 JAPAN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 309 JAPAN RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 310 CHINA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 311 CHINA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 312 CHINA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 313 CHINA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 314 CHINA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 315 CHINA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 316 CHINA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 317 CHINA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 318 CHINA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 319 CHINA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 320 CHINA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 321 CHINA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 322 CHINA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 323 CHINA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 324 CHINA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 325 CHINA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 326 SOUTH KOREA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 327 SOUTH KOREA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 328 SOUTH KOREA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 329 SOUTH KOREA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 330 SOUTH KOREA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 331 SOUTH KOREA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 332 SOUTH KOREA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 333 SOUTH KOREA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 334 SOUTH KOREA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 335 SOUTH KOREA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 336 SOUTH KOREA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 337 SOUTH KOREA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 338 SOUTH KOREA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 339 SOUTH KOREA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 340 SOUTH KOREA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 341 SOUTH KOREA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 342 INDIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 343 INDIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 344 INDIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 345 INDIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 346 INDIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 347 INDIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 348 INDIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 349 INDIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 350 INDIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 351 INDIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 352 INDIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 353 INDIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 354 INDIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 355 INDIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 356 INDIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 357 INDIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 358 AUSTRALIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 359 AUSTRALIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 360 AUSTRALIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 361 AUSTRALIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 362 AUSTRALIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 363 AUSTRALIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 364 AUSTRALIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 365 AUSTRALIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 366 AUSTRALIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 367 AUSTRALIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 368 AUSTRALIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 369 AUSTRALIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 370 AUSTRALIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 371 AUSTRALIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 372 AUSTRALIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 373 AUSTRALIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 374 MALAYSIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 375 MALAYSIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 376 MALAYSIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 377 MALAYSIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 378 MALAYSIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 379 MALAYSIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 380 MALAYSIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 381 MALAYSIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 382 MALAYSIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 383 MALAYSIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 384 MALAYSIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 385 MALAYSIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 386 MALAYSIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 387 MALAYSIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 388 MALAYSIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 389 MALAYSIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 390 THAILAND INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 391 THAILAND INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 392 THAILAND VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 393 THAILAND QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 394 THAILAND TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 395 THAILAND BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 396 THAILAND MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 397 THAILAND VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 398 THAILAND INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 399 THAILAND LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 400 THAILAND DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 401 THAILAND INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 402 THAILAND INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 403 THAILAND INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 404 THAILAND INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 405 THAILAND RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 406 INDONESIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 407 INDONESIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 408 INDONESIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 409 INDONESIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 410 INDONESIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 411 INDONESIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 412 INDONESIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 413 INDONESIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 414 INDONESIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 415 INDONESIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 416 INDONESIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 417 INDONESIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 418 INDONESIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 419 INDONESIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 420 INDONESIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 421 INDONESIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 422 SINGAPORE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 423 SINGAPORE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 424 SINGAPORE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 425 SINGAPORE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 426 SINGAPORE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 427 SINGAPORE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 428 SINGAPORE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 429 SINGAPORE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 430 SINGAPORE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 431 SINGAPORE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 432 SINGAPORE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 433 SINGAPORE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 434 SINGAPORE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 435 SINGAPORE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 436 SINGAPORE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 437 SINGAPORE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 438 PHILIPPINES INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 439 PHILIPPINES INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 440 PHILIPPINES VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 441 PHILIPPINES QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 442 PHILIPPINES TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 443 PHILIPPINES BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 444 PHILIPPINES MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 445 PHILIPPINES VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 446 PHILIPPINES INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 447 PHILIPPINES LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 448 PHILIPPINES DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 449 PHILIPPINES INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 450 PHILIPPINES INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 451 PHILIPPINES INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 452 PHILIPPINES INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 453 PHILIPPINES RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 454 REST OF ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 455 SOUTH AMERICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 456 SOUTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 457 SOUTH AMERICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 458 SOUTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 459 SOUTH AMERICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 460 SOUTH AMERICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 461 SOUTH AMERICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 462 SOUTH AMERICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 463 SOUTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 464 SOUTH AMERICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 465 SOUTH AMERICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 466 SOUTH AMERICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 467 SOUTH AMERICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 468 SOUTH AMERICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 469 SOUTH AMERICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 470 SOUTH AMERICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 471 SOUTH AMERICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 472 BRAZIL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 473 BRAZIL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 474 BRAZIL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 475 BRAZIL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 476 BRAZIL TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 477 BRAZIL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 478 BRAZIL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 479 BRAZIL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 480 BRAZIL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 481 BRAZIL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 482 BRAZIL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 483 BRAZIL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 484 BRAZIL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 485 BRAZIL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 486 BRAZIL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 487 BRAZIL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 488 ARGENTINA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 489 ARGENTINA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 490 ARGENTINA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 491 ARGENTINA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 492 ARGENTINA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 493 ARGENTINA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 494 ARGENTINA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 495 ARGENTINA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 496 ARGENTINA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 497 ARGENTINA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 498 ARGENTINA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 499 ARGENTINA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 500 ARGENTINA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 501 ARGENTINA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 502 ARGENTINA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 503 ARGENTINA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 504 REST OF SOUTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 505 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 506 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 507 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 508 MIDDLE EAST AND AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 509 MIDDLE EAST AND AFRICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 510 MIDDLE EAST AND AFRICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 511 MIDDLE EAST AND AFRICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 512 MIDDLE EAST AND AFRICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 513 MIDDLE EAST AND AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 514 MIDDLE EAST AND AFRICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 515 MIDDLE EAST AND AFRICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 516 MIDDLE EAST AND AFRICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 517 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 518 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 519 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 520 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 521 MIDDLE EAST AND AFRICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 522 SOUTH AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 523 SOUTH AFRICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 524 SOUTH AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 525 SOUTH AFRICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 526 SOUTH AFRICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 527 SOUTH AFRICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 528 SOUTH AFRICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 529 SOUTH AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 530 SOUTH AFRICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 531 SOUTH AFRICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 532 SOUTH AFRICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 533 SOUTH AFRICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 534 SOUTH AFRICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 535 SOUTH AFRICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 536 SOUTH AFRICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 537 SOUTH AFRICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 538 U.A.E. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 539 U.A.E. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 540 U.A.E. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 541 U.A.E. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 542 U.A.E. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 543 U.A.E. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 544 U.A.E. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 545 U.A.E. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 546 U.A.E. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 547 U.A.E. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 548 U.A.E. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 549 U.A.E. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 550 U.A.E. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 551 U.A.E. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 552 U.A.E. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 553 U.A.E. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 554 SAUDI ARABIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 555 SAUDI ARABIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 556 SAUDI ARABIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 557 SAUDI ARABIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 558 SAUDI ARABIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 559 SAUDI ARABIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 560 SAUDI ARABIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 561 SAUDI ARABIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 562 SAUDI ARABIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 563 SAUDI ARABIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 564 SAUDI ARABIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 565 SAUDI ARABIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 566 SAUDI ARABIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 567 SAUDI ARABIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 568 SAUDI ARABIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 569 SAUDI ARABIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 570 EGYPT INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 571 EGYPT INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 572 EGYPT VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 573 EGYPT QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 574 EGYPT TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 575 EGYPT BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 576 EGYPT MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 577 EGYPT VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 578 EGYPT INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 579 EGYPT LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 580 EGYPT DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 581 EGYPT INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 582 EGYPT INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 583 EGYPT INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 584 EGYPT INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 585 EGYPT RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 586 ISRAEL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 587 ISRAEL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 588 ISRAEL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 589 ISRAEL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 590 ISRAEL TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 591 ISRAEL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 592 ISRAEL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 593 ISRAEL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)

TABLE 594 ISRAEL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 595 ISRAEL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)

TABLE 596 ISRAEL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 597 ISRAEL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 598 ISRAEL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)

TABLE 599 ISRAEL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 600 ISRAEL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 601 ISRAEL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 602 REST OF MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)